News

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.
Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...
The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...
The Food and Drug Administration announced Tuesday it has picked a new head of its center charged with vaccine approvals ... speed up the development of vaccines during the COVID-19 pandemic.
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...
R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...
Rudman Spergel, MD, director of clinical development at Moderna ... the technology to create one of the world’s first COVID-19 vaccines. In 2023, the company announced results from a phase ...
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...